002653SZSE
🚨 Material Event

CITIC Securities Company Limited's Listing Sponsorship Statement for Haisco Pharmaceutical Group Co., Ltd.'s Private Placement of A Shares

Haisco Pharmaceutical Group Co., Ltd.··27 pages

✨ AI Summary

CITIC Securities Company Limited issues a listing sponsorship statement for Haisco Pharmaceutical Group Co., Ltd.'s private placement of A shares. The statement details the offering's purpose, structure, and the sponsor's due diligence. Haisco aims to raise funds for new drug R&D and working capital, with the offering expected to enhance its capital strength and market position.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

CITIC Securities Company Limited's Listing Sponsorship Statement for Haisco Pharmaceutical Group Co., Ltd.'s Private Placement of A Shares

Statement

As the sponsor and sponsor representatives, we, in accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Administrative Measures for the Sponsorship Business of Securities Issuance and Listing," the "Administrative Measures for the Registration of Securities Issuance and Listing of Companies" (hereinafter referred to as the "Registration Measures"), and other relevant laws, administrative regulations, and the regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange, have acted with honesty, trustworthiness, diligence, and responsibility, and have strictly followed the legally formulated business rules and industry self-regulatory norms to issue this listing sponsorship statement, guaranteeing that the information provided is true, accurate, and complete.

Unless otherwise specified in this listing sponsorship statement, the relevant terms shall have the same meaning as in the "Prospectus for the Private Placement of A Shares by Haisco Pharmaceutical Group Co., Ltd. in 2025."

1. Basic Information of the Issuer

(1) Basic Information of the Issuer

Company Name: Haisco Pharmaceutical Group Co., Ltd.

English Name: Haisco Pharmaceutical Group Co., Ltd.

Stock Listing Exchange: Shenzhen Stock Exchange

A-share Stock Abbreviation: Haisco

Stock Code: 002653.SZ

Legal Representative: Yan Pangke

Registered Capital Before This Issuance: RMB 1,119,917,970

Registered Capital After This Issuance: RMB 1,140,892,480

Registered Address: No. 43, Wenxiong Avenue, Naitong District, Shannan City, Tibet

Business Scope: General items: Sales of chemical products (excluding licensed chemical products); sales of specialty chemical products (excluding hazardous chemical products); sales of formula for special medical purposes; medical research and experimental development; medical research and experimental development (excluding human stem cell, gene diagnosis and treatment technology development and application); technical services, technology development, technical consulting, technical exchange, technology transfer, technology promotion; professional design services; brand management; corporate image planning; market planning; conference and exhibition services; enterprise management consulting; enterprise management; business training (excluding training requiring permits, such as vocational skills training); data processing and storage support services; information system integration services; network technology services; import and export of goods; import and export of technology; domestic trade agency; import and export agency; supply chain management services; non-residential real estate leasing (excluding projects that require approval according to law, and independently carrying out business activities not prohibited or restricted by laws and regulations). Licensed items: Drug manufacturing; sales of pharmaceutical excipients; sales of food; wholesale of drugs; import and export of edible mushroom spawn; import and export of drugs; import and export of toxic chemicals; import of new chemical substances; online drug information services (projects requiring approval according to law can only be carried out after approval by the relevant departments, and specific business projects are subject to the permits of the relevant departments).

(2) Main Business, Core Technology, and R&D Capabilities of the Issuer

1. Main Business of the Issuer

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.